PetLife Pharmaceuticals, Inc. announced the signing of a contract with InnoVision Therapeutics, a major step towards the Center for Veterinary Medicine (CVM)/FDA testing and approval process for Vitalzul. PetLife, having already made a deposit with InnoVision, will immediately begin pre-INAD studies (Investigational New Animal Drug) of Vitalzul with InnoVision Therapeutics. InnoVision will work with the company to set up an initial meeting with the CVM to present and refine the regulatory pathway. Experts estimate that it will take between 18-24 months to complete the necessary pre-clinical and clinical studies needed for final FDA review.